515 related articles for article (PubMed ID: 33578191)
1. Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
Cree BAC; Bowen JD; Hartung HP; Vermersch P; Hughes B; Damian D; Hyvert Y; Dangond F; Galazka A; Grosso M; Jones DL; Leist TP
Mult Scler Relat Disord; 2021 Apr; 49():102695. PubMed ID: 33578191
[TBL] [Abstract][Full Text] [Related]
2. Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
Freedman MS; Coyle PK; Comi G; L Scarberry S; Damian D; Hyvert Y; Dangond F; Galazka A; Jack D; Lebson LA; Leist TP
Mult Scler J Exp Transl Clin; 2021; 7(1):2055217321990852. PubMed ID: 33717501
[TBL] [Abstract][Full Text] [Related]
3. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
Leist TP; Comi G; Cree BA; Coyle PK; Freedman MS; Hartung HP; Vermersch P; Casset-Semanaz F; Scaramozza M;
Lancet Neurol; 2014 Mar; 13(3):257-67. PubMed ID: 24502830
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study.
Freedman MS; Leist TP; Comi G; Cree BA; Coyle PK; Hartung HP; Vermersch P; Damian D; Dangond F
Mult Scler J Exp Transl Clin; 2017; 3(4):2055217317732802. PubMed ID: 29051829
[TBL] [Abstract][Full Text] [Related]
5. Serum neurofilament light chain correlations in patients with a first clinical demyelinating event in the REFLEX study: a
Kuhle J; Leppert D; Comi G; de Stefano N; Kappos L; Freedman MS; Seitzinger A; Roy S
Ther Adv Neurol Disord; 2024; 17():17562864241239101. PubMed ID: 38560407
[TBL] [Abstract][Full Text] [Related]
6. Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS.
de Stefano N; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Hodgkinson S; Prat A; Leocani L; Schmierer K; Sellebjerg F; Vermersch P; Wiendl H; Keller B; Roy S;
Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35701185
[TBL] [Abstract][Full Text] [Related]
7. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
Comi G; Cook SD; Giovannoni G; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett AC; Viglietta V; Greenberg SJ
J Neurol; 2013 Apr; 260(4):1136-46. PubMed ID: 23263473
[TBL] [Abstract][Full Text] [Related]
8. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study.
Comi G; De Stefano N; Freedman MS; Barkhof F; Uitdehaag BM; de Vos M; Marhardt K; Chen L; Issard D; Kappos L
J Neurol Neurosurg Psychiatry; 2017 Apr; 88(4):285-294. PubMed ID: 28039317
[TBL] [Abstract][Full Text] [Related]
10. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
Ali S; Paracha N; Cook S; Giovannoni G; Comi G; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Greenberg S; Scott DA; Joyeux A;
Clin Drug Investig; 2012 Jan; 32(1):15-27. PubMed ID: 22017519
[TBL] [Abstract][Full Text] [Related]
11. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
[TBL] [Abstract][Full Text] [Related]
12. Establishing the diagnosis of multiple sclerosis in Croatian patients with clinically isolated syndrome: 2010 versus 2017 McDonald criteria.
Habek M; Pavičić T; Ruška B; Pavlović I; Gabelić T; Barun B; Adamec I; Crnošija L; Krbot Skorić M
Mult Scler Relat Disord; 2018 Oct; 25():99-103. PubMed ID: 30059896
[TBL] [Abstract][Full Text] [Related]
13. Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study.
Freedman MS; De Stefano N; Barkhof F; Polman CH; Comi G; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Lehr L; Stubinski B; Jack DL; Kappos L
J Neurol; 2014 Mar; 261(3):490-9. PubMed ID: 24413638
[TBL] [Abstract][Full Text] [Related]
14. Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a.
Battaglini M; Vrenken H; Tappa Brocci R; Gentile G; Luchetti L; Versteeg A; Freedman MS; Uitdehaag BMJ; Kappos L; Comi G; Seitzinger A; Jack D; Sormani MP; Barkhof F; De Stefano N
Eur J Neurol; 2022 Jul; 29(7):2024-2035. PubMed ID: 35274413
[TBL] [Abstract][Full Text] [Related]
15. Conversion of clinically isolated syndrome to multiple sclerosis: a prospective study.
Kolčava J; Kočica J; Hulová M; Dušek L; Horáková M; Keřkovský M; Stulík J; Dostál M; Kuhn M; Vlčková E; Bednařík J; Benešová Y
Mult Scler Relat Disord; 2020 Sep; 44():102262. PubMed ID: 32570179
[TBL] [Abstract][Full Text] [Related]
16. Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study.
Rammohan K; Giovannoni G; Comi G; Cook S; Rieckmann P; Soelberg Sørensen P; Vermersch P; Hamlett A; Kurukulasuriya N;
Mult Scler Relat Disord; 2012 Jan; 1(1):49-54. PubMed ID: 25876451
[TBL] [Abstract][Full Text] [Related]
17. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan KW; Rieckmann P; Comi G; Dangond F; Hicking C; Vermersch P
Mult Scler; 2019 May; 25(6):819-827. PubMed ID: 29716436
[TBL] [Abstract][Full Text] [Related]
19. Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis.
Cortese R; Testa G; Assogna F; De Stefano N
CNS Drugs; 2024 Apr; 38(4):267-279. PubMed ID: 38489020
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis:
Vermersch P; Galazka A; Dangond F; Damian D; Wong SL; Jack D; Harty G
Curr Med Res Opin; 2021 Mar; 37(3):459-464. PubMed ID: 33331183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]